IPCA Laboratories Ltd SHARE PRICE [LIVE]

BSE: INE571A01020   NSE: IPCALAB   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
909.40
Change:
BSE
908.75
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in IPCA Laboratories Ltd

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

IPCALAB News

Frequently Asked Questions

What is the Share price of IPCA LABORATORIES LTD. (IPCALAB)?

IPCA LABORATORIES LTD. (IPCALAB) share price as of September 29, 2022, on NSE is Rs 909.40 (NSE) and Rs 908.75 (BSE) on BSE.

Can I buy IPCA LABORATORIES LTD. (IPCALAB) shares?

Yes, You can buy IPCA LABORATORIES LTD. (IPCALAB) shares by opening a Demat account with Angel One.

How do I buy IPCA LABORATORIES LTD. (IPCALAB) from Angel One?

IPCA LABORATORIES LTD. (IPCALAB) share can be brought through the following modes:
  1. Direct investment: You can buy IPCA LABORATORIES LTD. (IPCALAB) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to IPCA LABORATORIES LTD. (IPCALAB) shares.

About IPCALAB

Today's live share price for IPCA Laboratories Ltd is NSE: ₹ 909.40, BSE: ₹ 908.75 with a current market capitalization of .

Ipca Laboratories Limited (Ipca) was incorporated in 19th October of the year 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries. Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to `Ipca Laboratories Limited' in 6th August of the year 1964 and again name was changed to `Ipca Laboratories Private Limited' in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears in the year 1969 at Mumbai. The present management took over the company in November of the year 1975. In the year 1976, started domestic marketing operations, the first company to offer sugarcoated Chloroquine tablets. Launched formulations of Metoclopramide under brand name 'Perinorm' for the first time in India during the year 1978. After two years, in 1980, the company had launched formulations of Bromhexine for the first time in India. Ipca's first APIs plant was commissioned at Ratlam in the year 1984 and also in the same period the second formulations plant was commissioned at Ratlam itself. Ipca's first APIs Plant for manufacturing of Chloroquine Phosphate was set up at Ratlam in the year 1986. As at 9th August 1988, again the company had changed its name to `Ipca Laboratories Limited'. Ipca's status was converted to a Public Limited Company in 24th March of the year 1993 and also in the same year, the company had acquired Hoechst India's formulations unit at Kandla. During the year 1994, Ipca had acquired API Plant from BDH Pharmaceuticals (a subsidiary of E. Merck) at Indore. In the year 1995, the modern formulations plant at Athal (Silvassa) was came to line. After a year, in 1996, the company had commissioned new API R&D Centre at Mumbai. In 2000, received ISO 9001 certification for Athal Plant. The Company had incorporated two subsidiaries in Mauritius in the year of 2001 under the name of Solway Investments Ltd and 'Sundridge Management Ltd. during the year 2002, launched new domestic marketing division, Intima to promote established brands with a focus on micro-interior marketing and also in the same year incorporated wholly owned subsidiary in Brazil under the name of Laboratories Ipca Do Brasil Ltd. Launched new domestic marketing division in the year 2003 as Activa, dedicated to Rheumatology Care. Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA in the same year 2003. Commissioned new formulation plant at Silvassa in the year 2004. Forbes selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia. Innotech Pharma Limited was merged with Ipca in August of the year 2005. During the same year, Ipca entered in to Joint Venture with Holley Group of China for marketing Artemisinin based API and Formulation. Joint Venture setup in SAIF Zone, Sharjah, U.A.E. and named as ACTIVA Pharmaceuticals FZC. Also acquired Cardiac brand ISORDIL from Wyeth Limited. Ipca had entered into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market in the year 2006. The Company's new plant at Dehradun was commenced operation from 5th May of the year 2006. As of January 2007, Ipca and Ranbaxy alliance had received U.S. FDA marketing approval for Atenolol Tablets. Ipca's New Biotech Research & Development Unit was inaugurated at Mumbai in March of the same year 2007. Ipca had awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. Ipca had received final approval from the US FDA, for Metoclopramide tablets in June 2008. The Company had signed a partnership agreement with Clinton Foundation in July of the same year 2008. The Company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same.

Read more